18 related articles for article (PubMed ID: 21852056)
1. Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring.
Hardy M; Cabo J; Deliège A; Douxfils J; Gouin-Thibault I; Lecompte T; Mullier F
Res Pract Thromb Haemost; 2023 Nov; 7(8):102257. PubMed ID: 38193053
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity.
Amiral J; Amiral C; Dunois C
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34205548
[TBL] [Abstract][Full Text] [Related]
3. Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin.
Castro-López V; Murray B; Harris LF; O'Donnell JS; Killard AJ
Blood Coagul Fibrinolysis; 2012 Jan; 23(1):98-103. PubMed ID: 22089943
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.
Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ
Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908
[TBL] [Abstract][Full Text] [Related]
5. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy.
Clark NP; Delate T; Cleary SJ; Witt DM
Thromb Res; 2010 May; 125(5):402-5. PubMed ID: 19699510
[TBL] [Abstract][Full Text] [Related]
6. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas.
Harris LF; Castro-López V; Jenkins PV; O'Donnell JS; Killard AJ
Thromb Res; 2011 Dec; 128(6):e125-9. PubMed ID: 21824646
[TBL] [Abstract][Full Text] [Related]
8. Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays.
Castro-López V; Harris LF; O'Donnell JS; Killard AJ
J Pharm Biomed Anal; 2011 Dec; 56(5):992-7. PubMed ID: 21852056
[TBL] [Abstract][Full Text] [Related]
9. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.
Rosenberg AF; Zumberg M; Taylor L; LeClaire A; Harris N
J Pharm Pract; 2010 Jun; 23(3):210-6. PubMed ID: 21507816
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
